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Differences in cartilage thickness change (baseline to 12M) between prospective
KRs and non-KRs
TFTJ MFTC LFTC MT LT cMF cLF
All (24-60M)
P crude 0.027 0.23 0.007 0.025 0.003 0.70 0.053
P adjusted 0.002 0.18 0.0002 0.004 0.003 0.98 0.002
AUC 0.64 0.56 0.66 0.61 0.65 0.53 0.60
"Earlier" (24&36M)
P crude 0.09 0.34 0.047 0.018 0.0003 0.98 0.28
P adjusted 0.003 0.162 0.0003 0.0005 0.0002 0.72 0.021
AUC 0.69 0.60 0.68 0.71 0.74 0.53 0.54
"Later" (48&60M)
P crude 0.12 0.53 0.10 0.47 0.54 0.56 0.049
P adjusted 0.13 0.32 0.12 0.55 0.65 0.35 0.056
AUC 0.59 0.53 0.63 0.52 0.57 0.52 0.64
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S249score of these two lesions was associated with total WOMAC pain,
stiffness and dysfunction. Furthermore, popliteal cyst and sub-
gastocnemius bursa were signiﬁcantly associated with cartilage defects
in all compartments, and with radiographic osteophyte and MRI-
detected BMLs in medial tibiofemoral compartment. Longitudinally,
both baseline popliteal cyst (OR¼2.67 and 3.82 for medial tibial and
medial femoral, respectively, p<0.01) and total score of sub-
gastrocnemius bursa and popliteal cyst(OR¼2.15 and 2.91 for medial
tibial and medial femoral, respectively, p<0.01) were positively asso-
ciated with an increase in medial tibiofemoral cartilage defect. Baseline
popliteal cyst was also positively associated with an increase in BML
score before and after adjustment.
Conclusions: Popliteal cyst and subgastrocnemius bursa are associated
with not only symptoms, but also radiographic and MRI-detected
abnormalities of knee OA, suggesting that these cystic lesions may play
a pathological role in OA.
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THE LONG-TERM EFFECTS OF SYSADOA TREATMENT ON KNEE
OSTEOARTHRITIS SYMPTOMS AND PROGRESSION OF STRUCTURAL
CHANGES: PARTICIPANTS FROM THE OSTEOARTHRITIS INITIATIVE
PROGRESSION COHORT
J. Martel-Pelletier y, C. Roubille y, J.-P. Raynauld y, F. Abram z, M.
Dorais x, P. Delorme y, J.-P. Pelletier y. yUniv. of Montreal Hosp. Res. Ctr.
(CRCHUM), Montreal, QC, Canada; z Imaging Res. & Dev., ArthroLab Inc.,
Montreal, QC, Canada; x StatSci. Inc., Notre-Dame de l'Île-Perrot, QC,
Canada
Purpose: This study aimed at exploring the effects of commonly used
medication for the treatment of knee osteoarthritis (OA) on the
progression of the disease over a period of 24 consecutive months.
Methods: Participants were from the Osteoarthritis Initiative progres-
sion cohort (http://www.oai.ucsf.edu/) (n¼1,390) who met the
following criteria: 24 consecutive months of follow-up with complete
medical history, knee X-rays and MRI of the most symptomatic knee
(greatest WOMAC pain) at 0, 12 and 24 months, and who had no total
knee replacement during the follow-up. Using these criteria, 600
participants were found eligible. The knee radiograph data for joint
space width (JSW) and narrowing (JSN) were analyzed (OAI database)
and cartilage volume was assessed using fully-automated quantitative
magnetic resonance imaging as published.
Results: Of the 600 participants, 300 received continuous treatment for
24 months with commonly used pharmacological agents for OA
(NSAIDs, analgesics, etc., starting at least 1 month before baseline) with
or without () an OA slow acting drug (SYSADOA), namely glucos-
amine/chondroitin sulfate (Glu/CS, starting at least 6 months before
baseline). The other 300 had no OA treatment but could have received
the Glu/CS. The groups were named as follows: treated (OA treatment
Glu/CS) and untreated (no OA treatment  Glu/CS). The two groups
were balanced with the exception of a greater number of males (55% vs.
40%, p¼0.002) and higher body mass index (315 vs. 294, p¼0001)
and WOMAC scores (p<0.0001), as well as smaller JSW (3.431.89 vs.
3.801.70, p¼0.013) and greater Kellgren-Lawrence grade (p¼0.006) in
the treated vs. untreated group at baseline. The global knee cartilage
volume was not signiﬁcantly different between the two groups
(12.853.31 vs. 13.263.35 mm3). In the untreated group, less JSN at 12
months (+0.020.6 vs. ‑0.120.47, p¼0.057) and less cartilage volume
loss at 24 months in the medial central condyle (‑2.36.2 vs. ‑3.15.9,
p¼0.061) and plateau (‑2.36.7 vs. ‑4.28.5; p¼0.043) was found in
those taking the SYSADOA Glu/CS (n¼90) compared to those who were
not (n¼210). In the treated group, those who took the SYSADOA Glu/CS
(n¼113) had lower WOMAC scores at baseline (pain: 5.23.3 vs.
7.44.4, p<0.0001; stiffness: 2.81.5 vs. 3.21.9, p¼0.0373; disability:
16.110.4 vs. 21.314.0, p¼0.0004) compared to those who did not.
However, no differences in the changes in WOMAC scores were found
between the two subgroups over time. Among those who had a JSW at
baseline greater than the median (n¼148), the participants who
received Glu/CS presented smaller JSN at 12 (0.090.53 vs. ‑0.130.47,
p¼0.020) and 24 months (0.020.50 vs. ‑0.170.59, p¼0.092) and
demonstrated a statistically signiﬁcant reduction in cartilage volume
loss at 24 months in both the medial condyle (p¼0.01) and medial
compartment (p¼0.05) compared to those who did not.
Conclusions: Participants who received OA treatment showed more
severe disease symptoms and structural changes, which tended to
progress more rapidly over time. In both analyzed groups, those whotook Glu/CS had less symptoms and structural damage at baseline and
signiﬁcantly less JSN and cartilage volume loss over 24 months than
those who did not. The protective effect of Glu/CS on disease symptoms
and structural changes found in this observational study supports
results from previous studies.
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CARTILAGE THICKNESS LOSS AND INCIDENCE OF KNEE
REPLACEMENT IN A SUBSAMPLE FROM THE OSTEOARTHRITIS
INITIATIVE - A PROSPECTIVE COHORT STUDY
W. Hitzl y, W. Wirth y, S. Maschek y, S. Cotofana y, M. Nevitt z, M. John x, C.
Ladel k, F. Eckstein y. for the OAI investigatorsy Paracelsus Med. Univ.,
Salzburg, Austria; zOAI Coordinating Ctr., UCSF, San Francisco, CA, USA;
xNovartis Pharma AG, Basel, Switzerland; kMerck KG, Darmstadt,
Germany
Purpose: In the absence of disease modifying OA therapy, knee
replacements (KR) are projected to increase to more than 3 million
annually in the US by 2030. Imaging biomarkers capable of predicting
relevant clinical endpoints with socioeconomic impact can be of
particular value for testing the efﬁcacy of disease modifying interven-
tions in clinical trials. The purpose of this prospective cohort study was
to explore whether baseline to 12M longitudinal changes in cartilage
thickness (MRI) differ between Osteoarthritis Initiative (OAI) partici-
pants who received a KR between 12 and 60M vs. those who did not
(non-KRs), and whether potential differences are greater for “earlier”
KRs (24-36M) than for “later” KRs (48-60M).
Methods: 532 right knees from the OAI cohort with deﬁnite radiographic
KOA (KLG2-4 central readings) were studied. Segmentation of weight-
bearing femorotibial cartilages was performed by 12 readers (Chondro-
metrics GmbH) with blinding to acquisition order, using baseline and
12M coronal FLASH water-excitation 3T images. Cartilage thickness
(ThCtAB) was determined in themedial (MFTC) and lateral compartment
(LFTC) and in tibial (MT/LT) and (weight-bearing) femoral cartilage (cMF/
cLF) plates, respectively. Unadjusted p-values (t-tests) and p-values
adjusted for age and baseline BMI and KLG (general linear model) were
used to identify differences in rates of cartilage thickness loss (baseline to
12M) between KR cases and non-cases, with sex and TKA status as ﬁxed
effects. Corresponding AUCs were computed using ROC analyses.
Results: Of the 532 participants (63% women, age 639y, BMI 304.8),
58% were KLG2 and 42% KLG3/4; 329 had medial>lateral JSN, 100 later-
al>medial, and 103medial¼lateral JSN. 7.5% (n¼40) received a femoroti-
bial KRwithin 4yrs; 18 at 24-36M (“earlier”), and a similarnumber (n¼22)
at 48-60M (“later”). One case with femoro-patellar KR was excluded. Of
the femorotibial KRs, 75%werewomen and 25% KLG2; KR cases displayed
amean KLG of 3.1 (33%with lateral involvement), whereas non-KR knees
were on average KLG 2.5 (19% lateral). KRs had thinner baseline femo-
rotibial cartilage(-15%; p¼2.0*E-6) than non-KRs, with differences similar
medially and laterally. Observed longitudinal cartilage thickness changes
between baseline and 12M were greater in KRs than in non-KRs in all
regions, differences reaching statistical signiﬁcance in the total femo-
rotibial joint, the lateral compartment, and in both tibiae (Table 1). The
lateral femur also showed signiﬁcant differences when adjusting for age,
BMI and KLG (Table 1). The discrimination between “earlier” KRs (24-
36M) vs. non KRswas stronger than that between “later” KRs (48M-60M)
vs. non KRs (Table 1).
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S250Conclusions: Knees that were replaced (KRs) had lower baseline carti-
lage thickness and greater longitudinal (1 year) cartilage loss than non-
KRs, the differences being strongest in both tibiae. Cartilage loss in the
weight-bearing femur (a region commonly showing the greatest rate and
sensitivity to change), in contrast showed less discrimination. The ability
to discriminate between KRs and non-KRs was greater for “earlier” KRs
(within 2 years after measurement of cartilage loss) than for those who
received KR “later” (year 2-4 after measuring cartilage loss).
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PREDICTORS OF FATIGUE IN PATIENTS WITH HIP AND KNEE
OSTEOARTHRITIS
K.D. Allen y,z, H.B. Bosworth y,z, C.J. Coffman y,z, A.S. Jeffreys y, E.Z.
Oddone y,z, W.S. Yancy, Jr. y,z. yDurham VA Med. Ctr., Durham, NC, USA;
zDuke Univ. Med. Ctr., Durham, NC, USA
Purpose: Fatigue is emerging as an important outcome for patients
with osteoarthritis (OA), but little is known about factors that predict
fatigue severity. This study examined associations of demographic and
clinical factors with fatigue in a cohort of patients with hip and / or knee
OA.
Methods: Participants were n¼291 patients enrolled in a clinical trial of
a combined patient and provider intervention for managing OA at the
Durham Veterans Affairs Medical Center (mean age ¼ 61, SD¼9, 90%
male, 53% non-white - primarily African American). All measures were
from baseline assessments. Fatigue was assessed with a 10cm visual
analog scale (range 0-10) that asked participants to report how much
fatigue has been a problem for them during the past week; anchors
were “Fatigue is no problem” and “Fatigue is a major problem.”
Potential predictors included participant age, race (white vs. non-
white), gender, education (some vs. no college), self-rated health
(excellent, very good, or good vs. fair or poor), pain severity (Western
Ontario and McMasters University Osteoarthritis Index pain subscale),
insomnia (Insomnia Severity Index), and depressive symptoms (Patient
Health Questionnaire-8). Simple linear regression models examined
associations of each individual predictor variable with fatigue, then
a multivariable model was ﬁt including all predictors that were signif-
icantly associated (p<0.01) with fatigue in simple regression models.
Results: The mean fatigue score was 4.8 (SD¼3.1). In simple regression
models, older age was associated with slightly lower fatigue (b¼ - 0.07,
95%CI ¼ -0.1, -0.04; p<0.001), and the following were associate with
more fatigue: fair / poor self-rated health (b¼2.2, 95%CI ¼ 1.3, 3.1;
p<0.001), greater insomnia severity (b ¼ 0.21, 95%CI ¼ 0.2, 0.3,
p<0.001), greater pain severity (b¼ 0.4, 95%CI¼ 0.3, 0.5; p<0.001), and
greater depressive symptoms (b ¼ 0.35, 95%CI ¼ 0.3, 0.4; p<0.001). In
the multivariable model, variables that remained associated with
fatigue were insomnia severity (b ¼ 0.06, 95%CI ¼ 0.01, 0.1; p¼0.0),
pain severity (b ¼ 0.20, 95%CI ¼ 0.1, 0.3; p<0.001), depressive symp-
toms (b ¼ 0.21, 95%CI ¼ 0.1, 0.3; p<0.001).
Conclusions: Fatigue severity was relatively high in this cohort of
patients with OA; mean values on the fatigue visual analog scale were
comparable to those seen in patients with rheumatoid arthritis.
Demographic factors including age, as well as general health, were not
associated with fatigue in the multivariable model. However, key clin-
ical variables related to OA - pain, depressive symptoms, and insomnia -
were associated with more fatigue. These results highlight that fatigue
is part of a cluster of OA-related symptoms that generally worsen with
greater disease severity. Because of its impact on daily activities and
quality of life, fatigue is an important issue to address among patients
with OA.475
MEN WITH EARLY DEGREES OF KNEE OA HAVE ALTERATIONS IN
VOLUNTARY ACTIVITY OF THE VASTUS LATERALIS MUSCLE AND
DECREASES IN ECCENTRIC KNEE EXTENSOR TORQUE
S.M. Mattiello, P.R. Serrão, K. Gramani-Say, F.A. Vasilceac, G.C. Lessi, A.B.
Oliveira. UFSCar, São Carlos - SP, Brazil
Purpose:Weakness of the muscles around the knee joint is common in
individuals with knee OA, especially quadriceps muscle weakness.
Moreover, in these patients the failure of the muscular voluntary
activity has been considered an important contributing factor in
reducing the strength of knee extension. Therefore, investigating these
aspects is essential to directing rehabilitation programs. The aim of thisstudy was to evaluate the knee extensor torque (KET) and electro-
myographic (EMG) activity of subjects with early stages of knee oste-
oarthritis (OA) and to compare with healthy subjects.
Methods: Forty men participated in this study: control group (CG;
n¼18; healthy subjects; 51.86.4 years) and osteoarthritis group (OAG;
n¼22; subjects with grade I or II knee osteoarthritis; 528.1 years). The
assessment of knee extensor torque was performed using an isokinetic
dynamometer (Biodex Multi-Joint System 3, Biodex Medical Inc., NY,
USA). Concentric and eccentric KET were evaluated at angular speeds of
90/s and 180/s simultaneously with electromyographic activity eval-
uation of the Vastus Lateralis (VL) muscle(Root Mean Square value -
RMS). The data were analyzed using Statistica software (version 7,
StatSoft, Inc., Tulsa, USA). For the intergroup analysis, we used the
independent t-test and the Mann-Whitney U test (a<0.05).
Results: Signiﬁcant differences were found between the groups in
eccentric KET at 90/s (p¼0.01) and at 180/s (p¼0.04), and in RMS
during the eccentric contractions, also at both angular velocities
(p<0.01), with higher values for the CG.
Conclusion: Thus, men with grade I or II knee OA have decreased
strength of the eccentric KET and decreased in muscular voluntary
activity, indicating neuromuscular adaptations. The eccentric training of
the knee extensor muscles should be emphasized, beginning in the
early stages of the disease.
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THE EFFECT OF AGE ON THE WOMAC TOTAL WITH CONTINUOUS
VERSUS INTERMITTENT CELECOXIB TREATMENT IN PATIENTS WITH
OSTEOARTHRITIS
M. Noyes Essex, P. Bhadra Brown, G.H. Sands. Pﬁzer Inc, New York, NY,
USA
Purpose: Continuous nonsteroidal anti-inﬂammatory drug (NSAID)
treatment has been shown to be signiﬁcantly more efﬁcacious than
intermittent dosing, over a 22-week period, in preventing subsequent
ﬂares in patients with osteoarthritis (OA) of the knee or hip who
successfully treated an initial ﬂare. We set out to characterize the effect
of age on efﬁcacy, as measured by Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) Total score, of continuous
daily celecoxib treatment vs intermittent celecoxib treatment.
Methods: Exploratory analysis of a clinical trial was conducted to
determine if WOMAC Total score during a blinded post-randomization
period differed among patients aged less than 60 or 60 years or more.
858 patients aged 18 to 80 with OA of the knee or hip, meeting Amer-
ican College of Rheumatology criteria, were randomized to receive
celecoxib 200 mg qd either as “continuous” (daily) or “intermittent”
(only when needed to treat OA ﬂare meeting predeﬁned criteria)
treatment. Analyses were performed on the intention-to-treat (ITT)
population ( 1 dose of study medication post-randomization) and
ﬂare-modiﬁed ITT population (all ITT patients with OA ﬂares  14 + 2
days duration), using a 2-sided type I error rate of 0.05.
Results:Mean ages were 51.3 (n ¼ 236) and 67.2 (n ¼ 195) years in the
continuous groups and 51.2 (n ¼ 220) and 66.7 (n ¼ 207) years in the
intermittent groups. For patients aged < 60 years, WOMAC Total least
squares mean (LSM) change from randomization to ﬁnal visit was 1.10
(SD 0.95) in the continuous group and 5.32 (SD 0.98) in the intermittent
group (P < 0.002). LSM change from randomization to ﬁnal visit in
patients aged 60 years was 2.24 (SD 1.06) in the continuous group and
4.60 (SD 1.03) in the intermittent group (P < 0.111). Primary results
showed that while WOMAC Total scores were comparable at random-
ization, LSM increases (worsening) in WOMAC Total during double-
blind treatment were signiﬁcantly less in patients receiving continuous
treatment than those receiving intermittent treatment.
In the ﬂare-modiﬁed ITT population, WOMAC Total LSM change from
randomization to ﬁnal visit in patients aged < 60 years receiving
continuous treatment was -0.05 (SD 1.08) vs 3.66 (SD 1.21) in the
intermittent group (P< 0.023). LSM change from randomization to ﬁnal
visit in the  60 years ﬂare-modiﬁed ITT population was -0.22 (SD 1.26)
vs 2.72 (SD 1.23) in the continuous and intermittent groups, respec-
tively (P ¼ 0.097). WOMAC Total LSM increases were less in the
continuous group than the intermittent group, irrespective of patients’
age, though only signiﬁcantly in those aged < 60 years for both the ITT
and ﬂare-modiﬁed ITT populations. Negative LSM change indicates
improvement in WOMAC Total.
Conclusions: Daily celecoxib treatment was signiﬁcantly more efﬁca-
cious, as assessed by the WOMAC Total score, than intermittent use for
